Donanemab in Japanese Patients with Early Alzheimer ’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

ConclusionsThe overall efficacy and safety of donanemab in Japanese participants were similar to the global TRAILBLAZER-ALZ 2 population.Trial registrationClinicalTrials.gov identifier: NCT04437511.
Source: Neurology and Therapy - Category: Neurology Source Type: research